ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUIÁTRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SISTÉMICO

Andrea Cevallos Guerrero; Heidi Ángela Fernández; Ruth Jimbo Sotomayor; Gabriela Carolina Guevara; Diego Mera Orces; Fernando Naranjo-Saltos

doi:10.1016/j.rcreu.2020.12.003

ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUIÁTRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SISTÉMICO

Título traducido de la contribución: Adherencia al tratamiento en pacientes con trastornos neuropsiquiátricos difusos asociados a lupus eritematoso sistémico

Andrea Cevallos Guerrero
, Heidi Ángela Fernández^*
, Ruth Jimbo Sotomayor
, Gabriela Carolina Guevara
, Diego Mera Orces
, Fernando Naranjo-Saltos

^*Autor correspondiente de este trabajo

Producción científica: Revista › Artículo › revisión exhaustiva

1 Cita (Scopus)

Resumen

Introduction: Systemic lupus erythematosus (SLE) is a chronic disease that affects multiple systems and may include neurological and psychiatric events that could compromise treatment adherence and long-term outcomes in SLE. Objective: To evaluate treatment adherence in patients with diffuse neuropsychiatric disorders associated with SLE. Methodology: A cross-sectional descriptive study was conducted. Treatment adherence was evaluated with the Morisky Medication Adherence Scale (MMAS-8) in patients with diffuse neuropsychiatric disorders associated with SLE (cognitive impairment, psychosis, mood disorders, and anxiety). Results: A total of 60 patients with neuropsychiatric disorders associated with SLE were included. Thirteen patients (21.6%) had high adherence, 9 (15%) had medium adherence, and 38 patients (63.3%) had low treatment adherence. Conclusion: This study has identified that almost two-thirds of the participants (63.3%) had low treatment adherence.

Título traducido de la contribución	Adherencia al tratamiento en pacientes con trastornos neuropsiquiátricos difusos asociados a lupus eritematoso sistémico
Idioma original	Inglés
Páginas (desde-hasta)	26-30
Número de páginas	5
Publicación	Revista Colombiana de Reumatologia
Volumen	29
N.º	1
DOI	https://doi.org/10.1016/j.rcreu.2020.12.003 https://doi.org/10.1016/j.rcreu.2020.12.003
Estado	Publicada - 26 feb 2021

Nota bibliográfica

Publisher Copyright:
© 2021 Asociación Colombiana de Reumatología

Acceder al documento

10.1016/j.rcreu.2020.12.003
10.1016/j.rcreu.2020.12.003Licencia: Otros

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Cevallos Guerrero, A., Fernández, H. Á., Jimbo Sotomayor, R., Guevara, G. C., Mera Orces, D., & Naranjo-Saltos, F. (2021). ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUIÁTRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SISTÉMICO. Revista Colombiana de Reumatologia, 29(1), 26-30. https://doi.org/10.1016/j.rcreu.2020.12.003, https://doi.org/10.1016/j.rcreu.2020.12.003

@article{7eb73b930de443edbcb1e9a2f7951cd2,

title = "ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUI{\'A}TRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SIST{\'E}MICO",

abstract = "Introduction: Systemic lupus erythematosus (SLE) is a chronic disease that affects multiple systems and may include neurological and psychiatric events that could compromise treatment adherence and long-term outcomes in SLE. Objective: To evaluate treatment adherence in patients with diffuse neuropsychiatric disorders associated with SLE. Methodology: A cross-sectional descriptive study was conducted. Treatment adherence was evaluated with the Morisky Medication Adherence Scale (MMAS-8) in patients with diffuse neuropsychiatric disorders associated with SLE (cognitive impairment, psychosis, mood disorders, and anxiety). Results: A total of 60 patients with neuropsychiatric disorders associated with SLE were included. Thirteen patients (21.6\%) had high adherence, 9 (15\%) had medium adherence, and 38 patients (63.3\%) had low treatment adherence. Conclusion: This study has identified that almost two-thirds of the participants (63.3\%) had low treatment adherence.",

keywords = "Adherence, Anxiety, Depression, Ecuador, Lupus, Neuropsychiatric",

author = "\{Cevallos Guerrero\}, Andrea and Fern{\'a}ndez, \{Heidi {\'A}ngela\} and \{Jimbo Sotomayor\}, Ruth and Guevara, \{Gabriela Carolina\} and \{Mera Orces\}, Diego and Fernando Naranjo-Saltos",

note = "Publisher Copyright: {\textcopyright} 2021 Asociaci{\'o}n Colombiana de Reumatolog{\'i}a",

year = "2021",

month = feb,

day = "26",

doi = "10.1016/j.rcreu.2020.12.003",

language = "English",

volume = "29",

pages = "26--30",

journal = "Revista Colombiana de Reumatologia",

issn = "0121-8123",

publisher = "Asociacion Colombiana de Reumatologia",

number = "1",

}

Cevallos Guerrero, A, Fernández, HÁ, Jimbo Sotomayor, R, Guevara, GC, Mera Orces, D & Naranjo-Saltos, F 2021, 'ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUIÁTRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SISTÉMICO', Revista Colombiana de Reumatologia, vol. 29, n.º 1, pp. 26-30. https://doi.org/10.1016/j.rcreu.2020.12.003, https://doi.org/10.1016/j.rcreu.2020.12.003

TY - JOUR

T1 - ADHERENCIA AL TRATAMIENTO EN PACIENTES CON TRASTORNOS NEUROPSIQUIÁTRICOS DIFUSOS ASOCIADOS A LUPUS ERITEMATOSO SISTÉMICO

AU - Cevallos Guerrero, Andrea

AU - Fernández, Heidi Ángela

AU - Jimbo Sotomayor, Ruth

AU - Guevara, Gabriela Carolina

AU - Mera Orces, Diego

AU - Naranjo-Saltos, Fernando

PY - 2021/2/26

Y1 - 2021/2/26

N2 - Introduction: Systemic lupus erythematosus (SLE) is a chronic disease that affects multiple systems and may include neurological and psychiatric events that could compromise treatment adherence and long-term outcomes in SLE. Objective: To evaluate treatment adherence in patients with diffuse neuropsychiatric disorders associated with SLE. Methodology: A cross-sectional descriptive study was conducted. Treatment adherence was evaluated with the Morisky Medication Adherence Scale (MMAS-8) in patients with diffuse neuropsychiatric disorders associated with SLE (cognitive impairment, psychosis, mood disorders, and anxiety). Results: A total of 60 patients with neuropsychiatric disorders associated with SLE were included. Thirteen patients (21.6%) had high adherence, 9 (15%) had medium adherence, and 38 patients (63.3%) had low treatment adherence. Conclusion: This study has identified that almost two-thirds of the participants (63.3%) had low treatment adherence.

AB - Introduction: Systemic lupus erythematosus (SLE) is a chronic disease that affects multiple systems and may include neurological and psychiatric events that could compromise treatment adherence and long-term outcomes in SLE. Objective: To evaluate treatment adherence in patients with diffuse neuropsychiatric disorders associated with SLE. Methodology: A cross-sectional descriptive study was conducted. Treatment adherence was evaluated with the Morisky Medication Adherence Scale (MMAS-8) in patients with diffuse neuropsychiatric disorders associated with SLE (cognitive impairment, psychosis, mood disorders, and anxiety). Results: A total of 60 patients with neuropsychiatric disorders associated with SLE were included. Thirteen patients (21.6%) had high adherence, 9 (15%) had medium adherence, and 38 patients (63.3%) had low treatment adherence. Conclusion: This study has identified that almost two-thirds of the participants (63.3%) had low treatment adherence.

KW - Adherence

KW - Anxiety

KW - Depression

KW - Ecuador

KW - Lupus

KW - Neuropsychiatric

UR - https://www.scopus.com/pages/publications/85101624759

U2 - 10.1016/j.rcreu.2020.12.003

DO - 10.1016/j.rcreu.2020.12.003

M3 - Article

AN - SCOPUS:85101624759

SN - 0121-8123

VL - 29

SP - 26

EP - 30

JO - Revista Colombiana de Reumatologia

JF - Revista Colombiana de Reumatologia

IS - 1

ER -